Adrenal
Subtype work-up in primary aldosteronism (SPARTACUS) and pharmacotherapy of Cushing's disease (LINC-3).
- Trials
- 2
- Years
- 2016–2020
Sort
- 2020LINC-3Cushing's diseaseIn 137 adults with Cushing's disease, osilodrostat achieved control of mean 24-h urinary free cortisol in a randomised-withdrawal phase versus placebo.OR 13.7Read →
- 2016SPARTACUSPrimary aldosteronism subtypingIn 200 patients with primary aldosteronism, CT-based subtyping did not differ from adrenal-vein-sampling-based subtyping for antihypertensive intensity at 1 year.Read →